New Sales Forecast: Atopic dermatitis.
By Christina Vasiliou, Senior Analyst
4 February 2016
I joined Datamonitor Healthcare in early 2014, having completed an MPhil in Bioscience Enterprise at the University of C...
Read full bio
Datamonitor Healthcare’s latest sales forecast uses a patient-based approach to size the atopic dermatitis market opportunity across the US, Japan, and five major EU markets* during 2015–24.
Our research predicts that the atopic dermatitis market value will experience a strong compound annual growth rate of 15.6% between 2015-2024 predominantly due to the anticipated approval of dupilumab, the first biologic expected to enter the atopic dermatitis market.
Datamonitor Healthcare analyses the market dynamics, key therapies and the future pipelines, enabling you to successfully position your product in the atopic dermatitis market to ensure your company remains ahead of the competition.
Our sample extract highlights:
- Predicted sales figures ($) of dupilumab by country between 2015-2024
- Predicted sales figures ($) of the novel non-steroidal topical therapy, crisaborole, in the US between 2015–24
- Datamonitor Healthcare’s patient based forecast methodology
Explore our forecast on atopic dermatitis by downloading your exclusive extract from this market leading report >>
If you’re already a subscriber to Datamonitor Healthcare, click here to access the full report.